Peroxisome proliferators (PPs) represent a diverse group of chemicals including fibrate hypolipidemic drugs, phthalate ester plasticizers, and herbicides, with a high likelihood of clinical, occupational, and environmental exposure to humans (Klaunig et al., 2003) . Exposure of rodents to PPs initiates short-term pleiotropic responses including hepatomegaly, peroxisome proliferation, and increases in fatty acid oxidation in liver, kidney, and heart through induction of genes encoding enzymes for fatty acid metabolism (Cattley, 2004; Gibson et al., 1982; Lazarow and De Duve, 1976; Reddy and Krishnakantha, 1975) . Long-term treatment of rodent with PPs results in increased incidence of hepatocellular carcinomas (Cattley, 2004; Cattley et al., 1998; Reddy et al., 1980) . Humans are resistant to the induction of peroxisome proliferation and the carcinogenic effects induced by fibrate drugs; however, the molecular mechanism is not completely understood (Cattley et al., 1998; Klaunig et al., 2003) .
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily. Three isoforms of PPARs (a, b/d, and c) have been identified in different tissues. PPARa is mainly expressed in organs that are critical in fatty acid catabolism, such as liver, heart, and kidney. PPARs function as transcription factors through the classic liganddependent nuclear hormone receptor mechanism. Upon binding to their ligands, PPARs undergo conformational changes that allow corepressor release and coactivator recruitment, heterodimerization with retinoid X receptor, and selective binding to specific DNA sequences termed PPs response elements (PPREs) in the promoters of target genes (Berger and Moller, 2002) . PPARa serves a fundamental role in mammals by acting as a central modulator of signaling molecules that mediate changes in gene expression to maintain lipid homeostasis. In addition, PPARa has also been linked to the regulation of genes important in cell growth and differentiation (Shearer and Hoekstra, 2003) .
The use of the ppara-null mouse model reveals that PPARa is responsible for PP-induced pleiotropic responses in mice (Lee et al., 1995; Peters et al., 1997) . Thus, the difference in PPARa function between rodents and humans is proposed to explain the species difference in response to PPs. Currently, there are no reliable systems other than direct exposure in humans to quantitatively assess PP-induced pleiotropic effects, therefore a PPARa-humanized mouse model would be of great value to explore the molecular mechanism underlying the species difference. Recently, a liver-specific humanized PPARa mouse model was established using the regulatable tet-OFF system to evaluate the difference in hepatocarcinogenic responses after treatment with PPs (Cheung et al., 2004; Morimura et al., 2006) . To further determine the species difference mediated by PPARa, a new PPARa-humanized transgenic mouse was generated that has the complete human PPARa (hPPARa) gene on a P1 phage artificial chromosome (PAC) genomic clone, introduced onto the mouse ppara-null background. This new line of PPARahumanized mice, designated hPPARa PAC , express hPPARa not only in liver but also in other tissues. Employing this model, the various PP-induced responses were examined compared to wildtype (Wt) mice under same treatment.
MATERIALS AND METHODS
Generation of PPARa-humanized transgenic mice. A PAC genomic library (Genome Systems, St Louis, MO) was screened using hPPARa cDNA (Cheung et al., 2004) . The PAC clone containing the complete hPPARa gene including 5# and 3# flanking sequence was verified by southern blot analysis with 32 P-end-labeled DNA oligonucleotide probes recognizing specific regions (exon 1 and 8 and -10 kb upstream of hPPARa gene). The purified PAC clone was linearized using restriction enzyme digestion and microinjected into fertilized FVB/N mouse eggs by the NCI transgenic Core Facility, Laboratory Animal Sciences Program, Science Applications International Program (Frederick, MD). Transgenic founders were bred further with ppara-null mice. Mice positive for the hPPARa transgene and the mouse ppara-null allele as determined by PCR genotyping were PPARa-humanized transgenic (designated hPPARa PAC or PAC) mice. The PAC mice were further bred with ppara-null mice for at least four generations onto an Sv129 background. The transgenic animals were screened by southern blot analysis or PCR of tail DNA. The primers for the hPPARa exon 1 were: 5#-CCA ATC TGG AAA CAG TAA ATT AAA CC-3# (forward) and 5#-GCA TCC AGA GAA CAA CCG TAA-3# (reverse), which yielded a 170-bp fragment. The primers for mouse mEH gene used as internal control were described previously (Cheung et al., 2004) .
Animal treatments. The mice were maintained under a standard 12-h light/12-h dark cycle with water and chow provided ad libitum. Handling was in accordance with animal study protocols approved by the Animal Care and Use Committee at National Cancer Institute. Some mice were administered Wy-14,643 or fenofibrate (0.1% or 0.2% [w/w], respectively, Bio-Serv, Frenchtown, NJ) in the diet for indicated time.
Hepatocyte proliferation. Hepatocyte proliferation was analyzed by the BrdU incorporation assay as previously described .
Serum lipids. For serum analysis, mice were deprived of food for overnight and blood was collected. Total triglycerides and free fatty acid were measured in serum using a commercial kit (Sigma, St Louis, MO).
Quantitative real-time PCR. Total RNA was isolated by mechanical disruption of indicated tissues with Trizol reagent (Invitrogen, Carlsbad, CA) following the manufacturer's protocol. The concentration of RNA was determined by spectrophotometry. cDNA was synthesized from an equivalent amount of total RNA from each sample using Superscript first strand synthesis system (Invitrogen). Primers were designed for real-time PCR using the Primer Express software (Applied Biosystems, Foster City, CA). The sequence and Genbank accession number for the forward and reverse primers used to quantify mRNA were showed in the Supplementary Table. Real-time reactions were carried out using SYBR Green PCR master mix (AB Applied Biosystems, Warrington, UK) using the ABI PRISM 7900 HT sequence detection system (AB Applied Biosystems). The following conditions were used for PCR: 94°C for 15 s, 60°C for 15 s, and 72°C for 30 s in 45 cycles. Relative expression levels of mRNA were normalized to GAPDH and analyzed for statistical significance.
Northern blot analysis. Ten micrograms of total RNA was electrophoresed on a 1.0% agarose gel containing 0.22M formaldehyde, transferred to a nylon membrane, and cross-linked by ultraviolet light exposure. Northern blot analysis was carried out as described previously (Akiyama et al., 2000) . Membranes were hybridized in ULTRAhyb buffer (Ambion, Austin, TX) with random primer 32 P-labeled cDNA probes following the manufacturer's protocol and washed with salt/detergent solution using standard procedures. miRNA analysis. miRNA were detected by 32 P-end labeling of antisense probes to miRNA sequence as described previously (Shah et al., 2007) .
Immunoblot analysis. Immunoblot analysis of PPARa was carried out on nuclear extracts of liver samples prepared using an NE-PER nuclear extraction kit (Pierce, Rockford, IL) and immunoblot analysis of peroxisomal membrane protein 70 (PMP70) was carried out on liver homogenates. Proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot using monoclonal anti-PPARa (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or rabbit anti-PMP 70 polyclonal antibodies (Abcam), respectively, and an enhanced chemiluminescence detection kit (Pierce). Goat anti-GAPDH (Santa Cruz Biotechnology, Inc.,) was used as a loading control.
Histological analyses. Mice were killed by over-exposure to carbon dioxide, and the livers were excised, fixed in 10% neutral buffered formalin (Fisher Scientific, Fair Lawn, NJ), embedded in paraffin, and 4-to 6-lm sections were prepared. Sections were stained with hematoxylin and eosin and were evaluated by light microscopy.
Data analysis. All data are presented as the mean ± SEM. The differences between groups were assessed by ANOVA. Differences were considered statistically significant at p < 0.05.
RESULTS

Generation of PPARa-Humanized Mice
The hPPARa PAC mouse line was created by use of a PAC clone containing the complete hPPARa gene sequence including 5# and 3# flanking sequences (Fig. 1A) . The integrated PAC gene was verified by southern blot analysis with a hPPARa cDNA and DNA oligonucleotide probes recognizing specific regions, e.g., exon 1 and 8 and -10 kb upstream of hPPARa gene. Mice that were positive for the hPPARa transgene and THE PPARa-HUMANIZED MOUSE containing the mouse ppara-null allele, as determined by PCR genotyping (Fig. 1B) , were designated hPPARa PAC mice.
The Expression and Distribution of hPPARa in hPPARa PAC Mice
To determine the expression and distribution of hPPARa RNA in hPPARa PAC mice, eight organs were collected and expression of hPPARa RNA determined by qPCR. The results showed that similar to mPPARa in Wt mice, hPPARa RNA in hPPARa PAC mice was expressed in organs or tissues with high fatty acid catabolism such as brown adipose tissue, liver, kidney, heart, and intestine and at very low levels in lung, white adipose tissue, and spleen ( Fig. 2A) . In agreement with RNA expression, hPPARa protein was highly expressed in the liver of hPPARa PAC mice to an extent similar to the mPPARa in Wt mice (Fig. 2B) . In addition, mPPARa in Wt mice and hPPARa in hPPARa PAC mice were upregulated by overnight fasting (Fig. 2C) indicating that the hPPARa gene is under similar transcriptional regulation as its mouse counterpart.
Induction of PPARa Target Genes in hPPARa PAC Mice
To examine the effect of activation of hPPARa on gene expression, induction of the known PPARa target genes were examined in liver, kidney, and heart of hPPARa PAC mice upon treatment with the clinically used lipid-lowering drug fenofibrate. Following 2 weeks of fenofibrate treatment, a robust induction in mRNA expression of genes encoding enzymes responsible for peroxisomal (ACOX), mitochondrial (MCAD, LCAD), microsomal (CYP4A), and cytosolic (ACOT) fatty acid metabolism were found in liver, kidney, and heart of both Wt and hPPARa PAC mice (Figs. 3A-C), indicating that hPPARa functions in the same manner as mPPARa to regulate fatty acid metabolism-associated genes. In addition, Wy-14,643 and fenofibrate treatment produced similar effects to the liverspecific humanized PPARa mouse line (Cheung et al., 2004) . Wy-14,643 treatment also resulted in decreased serum triglyceride levels in hPPARa PAC mice (Fig. 3D) , consistent with induction of expression of genes encoding fatty acid metabolism. Interestingly, the hypolipidemic effects of fibrates are generally explained by increased expression of lipoprotein lipase (LPL) and decreased expression of apolipoprotein C-III (Apo C-III) (Auwerx et al., 1996) . However, the alteration of these genes by Wy-14,643 treatment was only observed in Wt mice and not in hPPARa PAC mice (Figs. 3E-F) , suggesting that the hypolipidemic effect observed in hPPARa PAC mice are not through LPL and Apo C-III.
Differential Effects of Activation of Mouse and Human PPARa in Liver
The hallmark features of rodents upon short-term administration of PPs are hepatomegaly and peroxisome proliferation. Hepatomegaly was observed in the hPPARa PAC mice following 2 weeks of Wy-14,643 treatment as revealed by the increased liver to body weight ratio compared to untreated hPPARa PAC mice (Fig. 4A) . However, the extent of hepatomegaly was markedly lower in hPPARa PAC mice when compared with Wt mice under the same treatment (Fig. 4A) . Histologically, the livers of Wt mice treated with Wy-14,643 were hypertrophic with clear eosinophilic regions; these phenotypic effects were observed in both Wt and hPPARa PAC mice (Fig. 4B) .
To further explain the differences in hepatomegaly between Wt and hPPARa PAC mice upon PP treatment, hepatocyte proliferation was assessed by the bromodeoxyuridine (BrdU) incorporation assay. The immunohistochemistry analysis of BrdU-stained hepatocytes revealed a high degree of incorporation of BrdU in Wy-14,643-treated Wt mouse livers (Fig. 4C ) with a labeling index average of 21.8% compared with 1.1% in untreated Wt controls. In contrast, in hPPARa PAC mice, Wy-14,643 treatment did not increase the incorporation of BrdU (Fig. 4C) with average labeling indices of 1.0% compared with 0.8% in the untreated control hPPARa PAC mice. Consistent with this finding, Wy-14,643 treatment resulted in a marked induction in the expression of CDK4 and cyclin D1 in the livers of Wt mice (Fig. 4D) . However, the expression of these genes were unaffected by Wy-14,643 treatment in hPPARa PAC mice. These data were in agreement with the liver-specific PPARahumanized mice that showed no increase in incorporation of BrdU into hepatocytes upon treatment with Wy-14,643 (Cheung et al., 2004) and further confirmed that activation of hPPARa does not induce hepatocyte proliferation.
To determine whether peroxisome proliferation occurred in the hPPARa PAC mice upon administration of PPs, the protein levels of the major PMP70 (a marker of peroxisome proliferation) were examined by Western blot analysis. Following 2-week treatment of Wy-14,643 feeding, induction of PMP70 was observed in the Wt mice, and this induction was also observed in hPPARa PAC mice (Fig. 4E ). This result indicates that PP treatment induced peroxisome proliferation in hPPARa PAC mice.
Different Induction of Genes by Activation of Mouse and Human PPARa in Liver
Induction of hepatic genes by PP treatment has been extensively investigated (Cariello et al., 2005; CherkaouiMalki et al., 2001; Stauber et al., 2005; Wong and Gill, 2002; Yadetie et al., 2003; Yamazaki et al., 2002) . The induction of various genes by Wy-14,643 in Wt and hPPARa PAC mice was examined first by microarray analysis followed by confirmation and quantitation by qPCR (Table 1) . More genes were induced by Wy-14,643 in Wt mice than in hPPARa PAC mice. Importantly, the oncogene gene c-myc was not induced in hPPARa PAC mice correlating with lack of hepatocyte FIG. 3. Induction of PPARa target genes in hPPARa PAC mice. (A-C) Induction of PPARa target genes by fenofibrate (Feno) was analyzed by qPCR in liver, kidney, and heart from 8-to 10-week-old mice after 2 weeks of treatment. Values are mean ± SEM (n ¼ 3-4); ACOX, acyl-coenzyme A oxidase; MCAD, mediumchain acyl-CoA dehydrogenase; LCAD, medium-chain acyl-CoA dehydrogenase; CYP4A, cytochrome P450 4A and ACOT, acyl-CoA thioesterase. (D) Serum total triglycerides analysis in 8-to 10-week-old mice. WY, Wy-14,643. Values are mean ± SEM (n ¼ 4-6); *p < 0.05 compared with Wt control. (E and F) Induction of LPL and apo C-III mRNA by PP was analyzed by q-PCR in the liver from 8-to 10-week-old mice; Values are mean ± SEM (n ¼ 3-4) *p < 0.05 compared with Wt control. THE PPARa-HUMANIZED MOUSE proliferation in hPPARa PAC mice. Moreover, genes encoding cell-surface proteins such as Anxa2, CD39, CD63, Ly6D, and CD24a and several other genes such as Cidea, Cidec, Dhrs8, and Hsd11b were also not induced in hPPARa PAC mice. Interestingly, Sult2a1 was only induced in hPPARa PAC mice and not in Wt mice; this gene is also induced in human hepatocytes by PP (Fang et al., 2005) . The regulation of several of these genes have previously been demonstrated through a PPARa-dependent mechanism (Cariello et al., 2005; CherkaouiMalki et al., 2001; Stauber et al., 2005; Wong and Gill, 2002; Yadetie et al., 2003; Yamazaki et al., 2002) . Additional studies will be necessary to fully explore the molecular regulatory mechanism and the functional implication associated with these differentially regulated genes.
Let-7C miRNA Expression by Activation of Mouse and Human PPARa in Liver
Activation of PPARa alters hepatic miRNA expression (Shah et al., 2007) . Most importantly, let-7C, a miRNA critical in cell growth and shown to target c-myc, was inhibited by Wy-14,643 treatment in Wt mice. The regulation of let-7C was also examined in hPPARa PAC mice. The results showed that the expression levels of both pri-let-7C (Fig. 5A ) and mature let-7C (Fig. 5B) were significantly higher in hPPARa PAC mice compared to Wt mice. Wy-14,643 treatment decreased the expression of pri-let-7C (Fig. 5A ) and mature let-7C (Fig. 5B) in Wt mice, however, these effects were not observed in hPPARa PAC mice. In addition, the induction of c-myc by Wy-14,643 treatment in Wt mice did not occur in Wy-14,643-treated hPPARa PAC mice (Fig. 5C ). This is in agreement with the previous observation in liver-specific humanized PPARa (Shah et al., 2007) and further indicates that activation of hPPARa does not cause a change in hepatic miRNA and c-Myc gene expression.
DISCUSSION
It is well established that PPs via activation of PPARa exert differential effects in rodents and humans. A number of studies have analyzed the involvement of PPARa in the speciesspecificity upon exposure to PPs (for reviews see (Cattley, 2004; Hertz and Bar-Tana, 1998; Peters et al., 2005; Vanden Heuvel, 1999) . Recently, a liver-specific humanized PPARa mouse model provided a useful strategy for examining species difference on PPARa-mediated effects (Cheung et al., 2004; Morimura et al., 2006) . The hPPARa PAC mice were produced in order to determine the role of extrahepatic expression of the human receptor on the species-specific effects of PPs. The hPPARa PAC mice express hPPARa in metabolically active organs such as, liver, heart, and kidney at expression levels similar to the mPPARa in Wt mice. The hPPARa PAC mice represent the most relevant model for humans since the tissue distribution of PPARa is similar to that observed in Wt mice, and the hPPARa in hPPARa PAC mice is under regulation of its native promoter. Indeed, upregulation of hepatic mPPARa in Wt mice by fasting was mirrored by the hPPARa in hPPARa PAC mice. Thus, hPPARa PAC mice are an ideal animal model to study the pleitropic effects of hPPARa.
A decrease in response of hPPARa versus mPPARa to PPs is proposed to contribute to the species difference (Cattley, 2004) . Induction of PPARa target genes for fatty acid metabolism and a decrease in serum triglycerides by PP in hPPARa PAC mice indicates that hPPARa is functional in the mouse environment with respect to regulation of fatty acid metabolism. This is in agreement with the liver-specific PPARa-humanized mice that also exhibit these responses (Cheung et al., 2004) . Indeed, the DNA-binding domain (DBD) of hPPARa is 100% homologous with the mPPARa DBD suggesting that both hPPARa and mPPARa bind to the same PPRE-binding site in the promoter region of target genes. Transfection of hPPARa into murine hepatocytes increased PP-induced peroxisome proliferationrelated effects (Macdonald et al., 1999) . These results suggest that hPPARa and mPPARa do not differ in induction of target genes with known PPRE.
Interestingly, the increased expression of LPL and decreased expression of apo C-III are proposed to explain the hypolipidemic effects of PPs (Auwerx et al., 1996) . However, hPPARa PAC mice treated with PP exhibit lowered serum triglycerides without alteration of the expression of LPL and apo C-III. This indicates that the hypolidemic effects in rodents are mediated via other molecular regulatory mechanisms. It is also suggested that activation of PPARa by PPs stimulates hepatic fatty acid oxidation and thereby diminishing their incorporation into triglycerides and secretion as very low density lipoprotein (VLDL) (Froyland et al., 1997) . Consistent with this idea, a robust induction of the genes encoding enzymes for fatty acid oxidation by PP in hPPARa PAC mice were observed. Thus, the exact mechanism by which PPs exert their hypolipidemic effects needs reexamination.
On the other hand, the difference in the affinity of ligands for the human and mouse PPARa receptor was proposed to account for the species difference. The ligand-binding domain (LBD) of hPPARa is 94% homologous with mPPARa LBD. In vitro transactivation assays have previously shown that Wy-14,643 has higher affinity for rodent PPARa than humans PPARa, while fenofibrate has similar affinity for rodent and humans PPARa (Shearer and Hoekstra, 2003; Sher et al., 1993) . In the present study, WY-14,643 and fenofibrate exhibit the same capacity to induce known PPARa target genes in liver, kidney, and heart in both Wt and hPPARa PAC mice. This is in agreement with the liver-specific PPARa-humanized mice that also exhibit a similar capacity to induce PPARa target genes in liver by WY-14,643 and fenofibrate (Cheung et al., 2004) . Thus, the ligand affinity difference between mouse and human PPARa may not be critical under the conditions used in these studies.
Peroxisome proliferation, hepatomegaly, and increased hepatocyte proliferation are hallmark features of rodents upon administration of PPs. Peroxisome proliferation is not seen in the liver of patients receiving fibrate drugs (Peters et al., 2005) . Induction of genes encoding peroxisomal enzymes and induction of the major peroxisomal membrane protein by PP in hPPARa PAC mice indicate that activation of hPPARa induces peroxisome proliferation. These results suggest that peroxisome proliferation-related effects might be differentially regulated in mouse hepatocytes compared to human hepatocytes. The slight hepatomegaly observed in hPPARa PAC mice was due in large part to hepatoctye hypertrophy likely as a result of peroxisome proliferation since hepatocytes of these mice do not divide as do Wt mouse hepatocytes after PP treatment. This may explain the phenotypic difference in hepatomegaly between Wt and hPPARa PAC mice. Consistence with this phenotype, no induction of cell cycle genes such as cyclin D1 and CDK4 were observed in hPPARa PAC mice. These phenotypes are also similar to that found in the liverspecific PPARa-humanized mice (Cheung et al., 2004) that THE PPARa-HUMANIZED MOUSE exhibit no hepatocyte proliferation. As activation of hepatic PPARa is sufficient to induce hepatocyte proliferation , hPPARa does not activate genes required for cell proliferation as compared to the mPPARa. The species difference between rodents and humans may reflect the altered gene expression upon exposure to PPs. The identification of such genes is necessary to define the molecular events related to the species difference. The hPPARa PAC mouse model provides a way to define the genes mediated by PPARa between rodents and humans. The differential regulation of genes by mPPARa and hPPARa (Table 1) indicates that there is inherent difference in PPARa between rodents and humans in the regulation of these genes. Among the genes, c-myc is an important oncogene that is related to the liver cancer development (Calvisi and Thorgeirsson, 2005) . In addition, induction of CD24, Anxa2, CD39, and Ly6D by Wy-14,643 parallels their expression in various cancers (Dzhandzhugazyan et al., 1998; Fogel et al., 1999; Tanaka et al., 2000; Witz, 2000) . No induction of these genes in hPPARa PAC mice suggests the less carcinogenic potential of hPPARa PAC mice. On the other hand, increasing evidence has implicated the involvement of miRNA in tumorigenesis (Calin et al., 2004) . Wy-14,643 was demonstrated to repress the expression of miRNA let-7C through a PPARadependent manner and subsequently increase c-myc and the oncogenic mir-17-92 cluster (Shah et al., 2007) . However, this effect was not observed in hPPARa PAC mice. Interestingly, hPPARa PAC mice demonstrated an increased expression level of let-7C as compared to Wt mice. These results also support the less carcinogenic potential of hPPARa PAC mice. As liver-specific PPARa-humanized mice do not develop liver cancer after Wy-14,643 treatment (Morimura et al., 2006) , it is thus expected that hPPARa PAC mice will not produce liver cancer after long-term treatment of PPs. Further efforts are required to define the molecular regulatory mechanisms and identify the effects exerting by these genes.
In conclusion, the results from hPPARa PAC mouse model demonstrate that effects of PPs on peroxisome proliferation and lipid metabolism are distinct from the effects of PPs on hepatomegaly and hepatocyte proliferation. The intrinsic differences in PPARa may contribute to the species specificity of PPs. However, it should be noted that these factors are not sufficient to determine the species difference since human hepatocytes did not demonstrate a marked induction of peroxisome proliferation, therefore other intrinsic differences must be present between rodent and human hepatocytes. It is therefore conceivable that hepatocytes may lack or over-express coregulators in a species-specific manner that might facilitate or inhibit PPARa-mediated gene expression. Identification of these specific factors would enhance our understanding of the molecular mechanisms of species difference of PPs.
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